CAS Registry Number comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
=== March === 11 March – Clive Revill, actor (The Empire Strikes Back, Irma La Douce, Oliver!) (born 1930). 13 March – Brian McMahon, venereologist, army officer, medical superintendent (Wakari Hospital, Dunedin Hospital) and lecturer (University of Otago) (born 1929). 14 March – Anne Nightingale, nurse, chair of the Nursing Council (1975–1984) (born 1932). 16 March – Gordon H. Brown, art historian, gallery director (Waikato Art Gallery, Sarjeant Gallery), and artist (born 1931). 20 March – Matt Mitchell, sailor (Team New Zealand, Alinghi, Oracle Team USA) (born c. 1971). 21 March – Nick Carter, lawyer and judge, Māori Land Court judge (1989–2002) (born 1935). 22 March – Alex Wyllie, rugby union player (Canterbury, national team) and coach (Canterbury, national team, Argentina) (born 1944). 31 March Sir Roger Clifford, 7th Baronet (born 1936). Ron Jones, obstetrician and gynaecologist (National Women's Hospital, University of Auckland), whistleblower in the "Unfortunate Experiment" (born 1939).
=== Method Development === Method development of chiral chromatography is still done by screening of columns from the various classes of chiral columns. While chiral separation mechanisms are understandable in certain scenarios, and the retention characteristics of analytes within the chromatographic columns can occasionally be elucidated, the precise combination of chiral stationary phases (CSPs) and mobile-phase compositions that required to effectively resolve a specific enantiomeric pair often remains elusive. The chemistry of CSP ligands significantly influences the creation of in-situ diastereomeric complexes upon the stationary phase surface. However, other method's conditions, such as mobile-phase solvents, their composition, mobile phase additives and column temperature can play equally critical roles. The final resolution of the enantiomers is the outcome of combination of intermolecular forces, and even a subtle change in them can determine the success or failure of separation. This complexity prevents from establishing routine method-development protocols that are universally applicable to a diverse range of enantiomers. In fact, sometimes the outcome of previous unsuccessful experiments do not provide any clue for the subsequent steps.
The Japanese Hisatugu Numata developed the first panoramic radiograph in 1933/34. This was followed by the development of intraoral panoramic X-ray units, in which the X-ray tube is placed intraorally (inside the mouth) and the X-ray film extraorally (outside the mouth). At the same time, Horst Beger from Dresden in 1943 and the Swiss dentist Walter Ott in 1946 worked on the Panoramix (Koch & Sterzel), Status X (Siemens) and Oralix (Philips). Intraoral panoramic devices were discontinued at the end of the 1980s because the radiation exposure was too high in direct contact with the tongue and oral mucosa due to the intraoral tube.
Their rough endoplasmic reticulum and Golgi apparatus were still not well developed, indicating that despite the change in shape, the fibroblasts still remained mostly in a resting phase. Few newly released materials were seen adjacent to the fibroblasts. The ground substance content in the infant Reinke's space seemed to decrease over time, as the fibrous component content increased, thus slowly changing the vocal fold structure.
Sources: en.wikipedia.org
==== Effects ==== RO5073012 by itself has no effect on locomotor activity in normal mice. It dose-dependently suppresses cocaine-induced hyperlocomotion (a psychostimulant-like effect) in rats, with near-complete suppression of cocaine-induced locomotor stimulation at the highest dose of RO5073012. Other TAAR1 agonists, including both partial agonists and full agonists, likewise suppress psychostimulant-induced hyperlocomotion. Conversely however, and in contrast to other TAAR1 partial agonists, RO5073012 non-significantly reduced the locomotor activity induced by amphetamine in normal mice. The reasons for this difference from other TAAR1 partial agonists are unclear, though RO5073012 has notably lower TAAR1 efficacy than other TAAR1 partial agonists. RO5073012 reduces basal locomotor activity in transgenic mice with TAAR1 overexpression. Amphetamine produces only weak locomotor stimulation in mice with TAAR1 overexpression, and RO5073012, by antagonizing the TAAR1, has been found to restore dextroamphetamine-induced hyperlocomotion in this context.
=== Diagnostic tests === The initial tests for thalassemias are: Complete blood count (CBC): Checks the number, size, and maturity of blood cells. Hemoglobin of less than 10 g/dl may indicate a carrier, below 7 g/dl is indicative of thalassemia major. In thalassemia major, mean corpuscular volume (MCV) are less than 70 fl, in thalassemia intermedia, MCV levels are below 80 fl (The normal range for MCV is 80–100 fl). The Mentzer index can be a pointer for diagnosis of thalassemia; it can be calculated from a CBC report. Peripheral blood smear: A blood smear examined under a microscope can show red blood cells that are abnormal in shape (poikilocytosis or codocytes), color (hypochromic), or size (microcytic), as well as those with abnormal inclusions (Heinz bodies). Serum iron and ferritin: these tests are needed to rule out iron-deficiency anemia. For an exact diagnosis, the following tests can be performed:
== Incident and aftermath == RaDonda Vaught began work as a nurse at Vanderbilt University Medical Center in December 2015. On December 24, 2017, 75-year-old Charlene Murphey was admitted to the hospital for a subdural hematoma. Two days later, Vaught, a registered nurse, was instructed to administer Versed (midazolam, a sedating drug) to Murphey, but instead administered vecuronium (a paralyzing drug). Murphey was to be given Versed prior to an MRI scan. Vaught initially tried to withdraw Versed from an automated dispensing cabinet which was designed to communicate with the hospital's Medication Administration Record (MAR). Though an order for the intended medication (Versed) was present in Murphey's MAR, Vaught "couldn't find [it] in Murphey's profile" in the dispensing cabinet after typing "VE" into its search function without realizing she should have been looking for its generic name, midazolam. Vaught then triggered an override that unlocked a much larger swath of medications and then searched for "VE" again, and selected the first medication in the list (vecuronium). Vaught claimed that using overrides was a common and daily occurrence; other witnesses similarly testified that technical issues and delays at medication cabinets were common, and that "nurses could use overrides to overcome those delays." Vaught looked at the back of the vial and saw that it needed to be reconstituted, but did not look at the front of the vial to verify that it was, indeed, Versed. Vaught proceeded to reconstitute the vial, went to the imaging unit, and administered a dose to Murphey.
==== Media, social, internal and foreign affairs ==== Defense, National Security and Emergency Committee Diplomatic and Consular Affairs Committee Public Freedoms and Human Rights Committee Media Committee Social Affairs and Labor Committee Youth and Sports Committee Family and Women Committee Endowments, Religious Affairs and Fatwa Committee
Sarcoidosis Granulomatous lung diseases Tuberculosis Fungal infections (e.g., histoplasmosis) Granulomatosis with polyangiitis Idiopathic pulmonary fibrosis Hypersensitivity pneumonitis Asthma Diagnosis of berylliosis is based on history of beryllium exposures, documented beryllium sensitivity, and granulomatous inflammation on lung biopsy. Given the invasive nature of a lung biopsy, diagnosis can also be based on clinical history consistent with berylliosis, abnormal chest x-ray or CT scan findings, and abnormalities in pulmonary function tests. The radiologic and pathologic features of berylliosis are very similar to sarcoidosis. Due to the strong clinical and histopathological resemblance of sarcoidosis and berylliosis, patients are sometimes misdiagnosed with sarcoidosis until the history of exposure to beryllium is elicited and beryllium hypersensitivity demonstrated with specific testing. Some studies suggest that up to 6% of all cases of sarcoidosis are actually berylliosis. The beryllium lymphocyte proliferation test (BeLPT) is the standard way of determining sensitivity to beryllium. The test is performed by acquiring either peripheral blood or fluid from a bronchial alveolar lavage, and lymphocytes are cultured with beryllium sulfate. Cells are then counted and those with elevated number of cells are considered abnormal. Those exposed persons with two abnormal BeLPT tested with peripheral blood, or one abnormal and one borderline result, are considered beryllium sensitized.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.